These cookies ensure basic functionalities and security features of the website, anonymously. Necessary cookies are absolutely essential for the website to function properly. Folx is starting their PrEP subscription at $90 a month, which is a huge improvement from the often exorbitant monthly price that set users back by up to $2000 per month previously. Folx has stepped right in to create their own version of the medication, which means that access to PrEP no longer has to be prohibitively expensive. This April, however, Gilead’s patent on PrEP expired, allowing other companies to create their own generic version of the 99%-effective drug. You all remember the charming Martin Shkreli, who famously hiked up the price of the HIV medication Daraprim in 2015? That’s just a small sample of how pharmaceutical CEOs can inflate prices at the drop of a hat, especially if they’re the sole owner of a patent. These limited offerings have led to high out-of-pocket prices and limits on access. This is pretty big news in general: although PrEP has been on the market since 2012, the two market brands (Truvada and Descovy) have been owned by Gilead Sciences. Folx, a subscription service for HRT and sexual health serving the trans and gender-nonconforming community, has started including the HIV prevention treatment PrEP amongst its offerings.
0 kommentar(er)
